Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

Market Cap	5.63B +38.5%
Revenue (ttm)	449.50M -12.1%
Net Income	30.31M -78.1%
EPS	0.21 -77.8%
Shares Out	146.32M
PE Ratio	184.08
Forward PE	n/a
Dividend	0.70 (1.84%)
Ex-Dividend Date	Jun 1, 2026

Volume	4,301,447
Open	40.33
Previous Close	38.06
Day's Range	38.11 - 40.48
52-Week Range	30.40 - 50.98
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Hangzhou Biotest Biotech

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits. In addition, the company is widely utilized across various medical institutions, judicial testing...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 613
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688767

Financial Performance

In 2025, Hangzhou Biotest Biotech's revenue was 448.01 million, a decrease of -19.91% compared to the previous year's 559.40 million. Earnings were 49.25 million, a decrease of -70.94%.